These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 33201172)

  • 1. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
    Boari GEM; Chiarini G; Bonetti S; Malerba P; Bianco G; Faustini C; Braglia-Orlandini F; Turini D; Guarinoni V; Saottini M; Viola S; Ferrari-Toninelli G; Pasini G; Mascadri C; Bonzi B; Desenzani P; Tusi C; Zanotti E; Nardin M; Rizzoni D
    Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33201172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
    Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
    Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.
    Cattaneo D; Pasina L; Maggioni AP; Giacomelli A; Oreni L; Covizzi A; Bradanini L; Schiuma M; Antinori S; Ridolfo A; Gervasoni C
    Drugs Aging; 2020 Dec; 37(12):925-933. PubMed ID: 33150470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
    Orbak Z; Laloglu F; Akat H
    Cardiol Young; 2021 Mar; 31(3):507-510. PubMed ID: 33183365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.
    Desai A; Santonocito OG; Caltagirone G; Kogan M; Ghetti F; Donadoni I; Porro F; Savevski V; Poretti D; Ciccarelli M; Martinelli Boneschi F; Voza A
    Medicina (Kaunas); 2020 Oct; 56(11):. PubMed ID: 33138045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
    Prats-Uribe A; Sena AG; Lai LYH; Ahmed WU; Alghoul H; Alser O; Alshammari TM; Areia C; Carter W; Casajust P; Dawoud D; Golozar A; Jonnagaddala J; Mehta PP; Gong M; Morales DR; Nyberg F; Posada JD; Recalde M; Roel E; Shah K; Shah NH; Schilling LM; Subbian V; Vizcaya D; Zhang L; Zhang Y; Zhu H; Liu L; Cho J; Lynch KE; Matheny ME; You SC; Rijnbeek PR; Hripcsak G; Lane JC; Burn E; Reich C; Suchard MA; Duarte-Salles T; Kostka K; Ryan PB; Prieto-Alhambra D
    BMJ; 2021 May; 373():n1038. PubMed ID: 33975825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
    Pablos JL; Galindo M; Carmona L; Lledó A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejón I; Alvaro-Gracia JM; Fernández Fernández D; Mera-Varela A; Manrique-Arija S; Mena Vázquez N; Fernandez-Nebro A; ;
    Ann Rheum Dis; 2020 Dec; 79(12):1544-1549. PubMed ID: 32796045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Valerio M; Amor-Garcia MA; Tejerina F; Sancho-Gonzalez M; Narrillos-Moraza A; Gimenez-Manzorro A; Manrique-Rodriguez S; Machado M; Olmedo M; Escudero-Vilaplana V; Villanueva-Bueno C; Torroba-Sanz B; Melgarejo-Ortuño A; Vicente-Valor J; Herranz A; Bouza E; Muñoz P; Sanjurjo M
    Int J Antimicrob Agents; 2021 Feb; 57(2):106249. PubMed ID: 33259918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
    Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
    J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
    Sargin Altunok E; Satici C; Dinc V; Kamat S; Alkan M; Demirkol MA; Toprak ID; Kostek ME; Yazla S; Esatoglu SN
    J Med Virol; 2022 Jan; 94(1):291-297. PubMed ID: 34491575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
    J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality.
    Rivera-Izquierdo M; Valero-Ubierna MDC; R-delAmo JL; Fernández-García MÁ; Martínez-Diz S; Tahery-Mahmoud A; Rodríguez-Camacho M; Gámiz-Molina AB; Barba-Gyengo N; Gámez-Baeza P; Cabrero-Rodríguez C; Guirado-Ruiz PA; Martín-Romero DT; Láinez-Ramos-Bossini AJ; Sánchez-Pérez MR; Mancera-Romero J; García-Martín M; Martín-delosReyes LM; Martínez-Ruiz V; Jiménez-Mejías E
    Med Clin (Barc); 2020 Nov; 155(9):375-381. PubMed ID: 32773165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study.
    Boari GEM; Bonetti S; Braglia-Orlandini F; Chiarini G; Faustini C; Bianco G; Santagiuliana M; Guarinoni V; Saottini M; Viola S; Ferrari-Toninelli G; Pasini G; Bonzi B; Desenzani P; Tusi C; Malerba P; Zanotti E; Turini D; Rizzoni D
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):373-381. PubMed ID: 33909284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
    J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
    Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.